drugset / Trial / NCT07180160
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Timeline
- Start
- 2025-09-25
- Primary completion
- 2027-09
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL1706 | Monoclonal antibody | — | — |
| Background | Abemaciclib | Small molecule | — | — |
| Background | Dalpiciclib | Small molecule | — | — |
| Background | Fulvestrant | Small molecule | — | — |
| Background | Palbociclib | Small molecule | — | — |
| Background | Ribociclib | Small molecule | — | — |